Add Formweb to your mobile device
Formulary synchronization in progress.
Please refer to Epic and your local
pharmacy
for available medications.
Search results for:
oritavancin
oritavancin
Brand names: Orbactiv
| Form | Strength |
|---|---|
| INJECTION, INTRAVENOUS | 400 mg |
Last updated: Aug. 25, 2022
Policies and procedures -
See Oritavancin criteria and pathway, approved by HM P&T 11/2019
Restricted to ID
Exclusion Criteria: Do NOT use if patient has osteomyelitis, diabetic foot infections, sepsis, confirmed/suspected bacteremia, necrotizing fasciitis, hemodynamic instability, or any other co-morbidities requiring inpatient admission.
Indication for Use: Acute bacterial skin and skin structure infections (ABSSIs) – cellulitis, erysipelas, wound infection, or major cutanenous abscess with a minimum lesion surface area of approximately 75 cm2
Consults, protocols, and therapeutic interchanges
Case Management & ASP Pharmacist Consult
Case Management Consult: Complete Patient Assistance Program / Insurance Verification Form and fax to 1.855.886.2482. Please call Orbactiv® Support at 1.844.672.2284 for questions.
Set up appointment for patient to follow-up with Infectious Disease physician in 3 – 5 days
Additional information
Houston Methodist Antimicrobial Stewardship page